Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

被引:1996
|
作者
Nielsen, TO
Hsu, FD
Jensen, K
Cheang, M
Karaca, G
Hu, ZY
Hernandez-Boussard, T
Livasy, C
Cowan, D
Dressler, L
Akslen, LA
Ragaz, J
Gown, AM
Gilks, CB
van de Rijn, MV
Perou, CM
机构
[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA
[5] Univ British Columbia, Vancouver Hosp & British Columbia Canc Agcy, Genet Pathol Evaluat Ctr, Vancouver, BC, Canada
[6] Stanford Univ, Dept Pathol, Med Ctr, Stanford, CA 94305 USA
[7] Stanford Univ, Dept Genet, Med Ctr, Stanford, CA 94305 USA
[8] Haukeland Univ Hosp, Dept Pathol, Gade Inst, N-5021 Bergen, Norway
[9] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada
[10] PhenoPath Labs, Seattle, WA USA
关键词
D O I
10.1158/1078-0432.CCR-04-0220
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Expression profiling studies classified breast carcinomas into estrogen receptor (ER)+/luminal, normal breast-like, HER2 overexpressing, and basal-like groups, with the latter two associated with poor outcomes. Currently, there exist clinical assays that identify ER+/luminal and HER2-overexpressing tumors, and we sought to develop a clinical assay for breast basal-like tumors. Experimental Design: To identify an immunohistochemical profile for breast basal-like tumors, we collected a series of known basal-like tumors and tested them for protein patterns that are characteristic of this subtype. Next, we examined the significance of these protein patterns using tissue microarrays and evaluated the prognostic significance of these findings. Results: Using a panel of 21 basal-like tumors, which was determined using gene expression profiles, we saw that this subtype was typically immunohistochemically negative for estrogen receptor and HER2 but positive for basal cytokeratins, HER1, and/or c-KIT. Using breast carcinoma tissue microarrays representing 930 patients with 17.4-year mean follow-up, basal cytokeratin expression was associated with low disease-specific survival. HER1 expression was observed in 54% of cases positive for basal cytokeratins (versus 11% of negative cases) and was associated with poor survival independent of nodal status and size. c-KIT expression was more common in basal-like tumors than in other breast cancers but did not influence prognosis. Conclusions: A panel of four antibodies (ER, HER1, HER2, and cytokeratin 5/6) can accurately identify basal-like tumors using standard available clinical tools and shows high specificity. These studies show that many basal-like tumors express HER1, which suggests candidate drugs for evaluation in these patients.
引用
收藏
页码:5367 / 5374
页数:8
相关论文
共 50 条
  • [1] Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
    Livasy, CA
    Karaca, G
    Nanda, R
    Tretiakova, MS
    Olopade, OI
    Moore, DT
    Perou, CM
    [J]. MODERN PATHOLOGY, 2006, 19 (02) : 264 - 271
  • [2] Basal-like invasive breast carcinoma: How specific are immunohistochemical markers?
    Baird, G. S.
    Goldstein, L. C.
    Gown, A. M.
    Barry, T. S.
    [J]. MODERN PATHOLOGY, 2008, 21 : 21A - 21A
  • [3] Basal-like invasive breast carcinoma: How specific are immunohistochemical markers?
    Baird, G. S.
    Goldslein, L. C.
    Gown, A. M.
    Barry, T. S.
    [J]. LABORATORY INVESTIGATION, 2008, 88 : 21A - 21A
  • [4] Immunohistochemical evaluation for myoepithelial markers, cytokeratin 8/18, EMA and vimentin in the basal-like subtype of invasive breast carcinoma
    Livasy, CA
    Karaca, G
    Peron, CM
    [J]. LABORATORY INVESTIGATION, 2005, 85 : 41A - 41A
  • [5] Immunohistochemical evaluation for myoepithelial markers, cytokeratin 8/18, EMA and vimentin in the basal-like subtype of invasive breast carcinoma
    Livasy, CA
    Karaca, G
    Perou, CM
    [J]. MODERN PATHOLOGY, 2005, 18 : 41A - 41A
  • [7] Identification of a basal-like subtype of breast ductal carcinoma in situ
    Livasy, Chad A.
    Perou, Charles M.
    Karaca, Gamze
    Cowan, David W.
    Maia, Diane
    Jackson, Susan
    Tse, Chiu-Kit
    Nyante, Sarah
    Millikan, Robert C.
    [J]. HUMAN PATHOLOGY, 2007, 38 (02) : 197 - 204
  • [8] MORPHOLOGIC AND CYTOPATHOLOGIC FEATURES OF BASAL-LIKE SUBTYPE OF BREAST CARCINOMA
    Ishihara, A.
    Yokoyama, S.
    Hirokawa, M.
    [J]. ACTA CYTOLOGICA, 2010, 54 (03) : 496 - 497
  • [9] Basal-Like Ductal Carcinoma In Situ: Immunohistochemical and Morphologic Characterization
    Devine, M. P.
    Rabban, J. T.
    Chen, Y. Y.
    [J]. MODERN PATHOLOGY, 2009, 22 : 37A - 37A
  • [10] Basal-Like Ductal Carcinoma In Situ: Immunohistochemical and Morphologic Characterization
    Devine, W. P.
    Rabban, J. T.
    Chen, Y. Y.
    [J]. LABORATORY INVESTIGATION, 2009, 89 : 37A - 37A